Karina Ng, Country President, Novartis Vietnam. — Photo courtesy of the company
Novartis Vietnam, an affiliate of the global healthcare company Novartis, announced the spin-off of Sandoz, its Generics & Biosimilar business, on April 1.
With effect from April 1, 2024, Sandoz will no longer be part of the Novartis business in Việt Nam.
In alignment with its new global strategy unveiled in 2022, Novartis Vietnam has now transformed into a focused innovative medicines business, concentrated on four core therapeutic areas: Cardiovascular and renal metabolic, Oncology, Immunology, and Neuroscience. Multiple significant in-market and pipeline assets in each of these areas offer the opportunity for Novartis Vietnam to meet the needs of those burdened by disease.
Karina Ng, Country President, Novartis Vietnam, said: “This is a truly historic moment for Novartis and Sandoz, as we begin new chapters as independent companies. From now on, Novartis will emerge as a fully focused innovative medicines company. As we enter this new era with a strong pipeline, we remain consistent in our commitment to expanding access to innovative treatments to patients in Việt Nam by building strategic partnerships with key stakeholders including the government, medical societies, patient communities, private sector, academies, and civil organisations.”
Novartis has been operating representative offices in Việt Nam since 2008. In February 2019, Novartis Vietnam Ltd. became one of the first multinational pharmaceutical companies to successfully transform into a foreign-invested enterprise and fully operationalize its import activities. Over the years, Novartis has made substantial contributions to support Việt Nam's economy and improve the health outcomes of patients in the country. In 2022, the full Novartis portfolio of medicines reached 5.6 million Vietnamese patients across 49 Novartis innovative medicine brands.
Novartis is also one of the leaders in R&D investment in Việt Nam. Since 2011, Novartis invested a total of US$25 million in 62 clinical trials in a broad range of therapeutic areas. Over 1,000 investigators and site staff were trained and gained experience in clinical trials conducted in over 130 sites across 30 hospitals. — VNS